MYCN deregulation is a feature of rhabdomyosarcoma tumorigenesis, defines groups of patients with a poor prognosis, and is a potential target for novel therapies.
No takes yet. Share an insight, caveat, or question.
Williamson et al. (2005) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: